PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing is organized by Clinical Care Options (CCO), LLC and will be held on Jun 01, 2019 at Radisson Blu Aqua Hotel, Chicago, Chicago, Illinois, United States of America.
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with metastatic breast cancer.
NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 2.0 contact hours.
NCCN designates this knowledge-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit.
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.
• Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating metastatic breast cancer
• Identify patients based on molecular changes and previous therapy that are most likely to benefit from treatments with PARP inhibitors
• Integrate single-agent PARP inhibitors into the treatment of appropriately selected patients with metastatic breast cancer
•Refer eligible patients with metastatic breast cancer to clinical trials of single-agent PARP inhibitors and combinations of PARP inhibitors with other anticancer therapies
Additional details will be posted as soon as they are available.
|Contact No. :||1-855-224-2241
Conference Fee Details
|Early Fee Last date||:||NA|